170 related articles for article (PubMed ID: 16607370)
21. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer.
Pfitzenmaier J; Ellis WJ; Hawley S; Arfman EW; Klein JR; Lange PH; Vessella RL
Urol Oncol; 2007; 25(3):214-20. PubMed ID: 17483018
[TBL] [Abstract][Full Text] [Related]
22. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
[TBL] [Abstract][Full Text] [Related]
23. Local-regional prostate cancer.
Jones MJ; Koeneman KS
Urol Oncol; 2008; 26(5):516-21. PubMed ID: 18774466
[TBL] [Abstract][Full Text] [Related]
24. ProstaScint and its role in the diagnosis of prostate cancer.
Mohammed AA; Shergill IS; Vandal MT; Gujral SS
Expert Rev Mol Diagn; 2007 Jul; 7(4):345-9. PubMed ID: 17620043
[TBL] [Abstract][Full Text] [Related]
25. The association between measures of progression and survival in castrate-metastatic prostate cancer.
Scher HI; Warren M; Heller G
Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
28. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
[TBL] [Abstract][Full Text] [Related]
29. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
30. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
31. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
[TBL] [Abstract][Full Text] [Related]
32. [First results of PET / CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy].
Winter A; Uphoff J; Henke RP; Wawroschek F
Aktuelle Urol; 2009 Sep; 40(5):294-9. PubMed ID: 19533582
[TBL] [Abstract][Full Text] [Related]
33. Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer.
Haseman MK; Rosenthal SA; Kipper SL; Trout JR; Manyak MJ
Urology; 2007 Aug; 70(2):303-8. PubMed ID: 17826494
[TBL] [Abstract][Full Text] [Related]
34. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
35. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
36. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer.
Rouprêt M; Fromont G; Bitker MO; Gattegno B; Vallancien G; Cussenot O
Urology; 2006 May; 67(5):1028-32. PubMed ID: 16698363
[TBL] [Abstract][Full Text] [Related]
37. An algorithm for managing the failure of external beam radiotherapy in prostate cancer.
Dudderidge T; Payne H; Emberton M
BJU Int; 2007 Sep; 100(3):518-27. PubMed ID: 17573894
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
Stock RG; Klein TJ; Cesaretti JA; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
[TBL] [Abstract][Full Text] [Related]
39. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases.
Banyard J; Bao L; Hofer MD; Zurakowski D; Spivey KA; Feldman AS; Hutchinson LM; Kuefer R; Rubin MA; Zetter BR
Clin Cancer Res; 2007 May; 13(9):2634-42. PubMed ID: 17473194
[TBL] [Abstract][Full Text] [Related]
40. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
